<DOC>
	<DOCNO>NCT02472717</DOCNO>
	<brief_summary>Exploratory , double-blind randomize , placebo-controlled , Phase II study evaluate effect ( ) short-term administration liraglutide , GLP-1R ( glucagon-like peptide-1 receptor ) agonist joint skin inflammation patient active Psoriatic Arthritis .</brief_summary>
	<brief_title>Psoriatic Arthritis Treated With Liraglutide Therapy : QUality Life Efficacy Study</brief_title>
	<detailed_description>The primary purpose study determine whether short-term ( 12-week ) administration GLP-1R agonist , liraglutide , improve joint skin swell patient active Psoriatic Arthritis compare placebo . Background : Psoriatic Arthritis systemic inflammatory T-cell disorder affect joint spine , associate elevate risk Type 2 Diabetes Cardiovascular Disease . In addition classical effect glycemic-lowering , GLP-1R agonist anti-diabetes agent also anti-inflammatory property may clinically useful patient inflammatory disease , particularly co-morbid metabolic disease . While small exploratory study patient psoriasis demonstrate GLP-1R agonist reduce severity skin plaque , dedicate prospective , randomize mechanistic study evaluate potential mechanism GLP-1R agonist exert anti-inflammatory action ( ) humans inflammatory disease lacking . Objectives : Primary objective evaluate clinical efficacy short-term liraglutide ( GLP-1R agonist ) administration severity joint skin inflammation patient active Psoriatic Arthritis . Secondary objective determine whether short-term liraglutide administration patient active psoriatic arthritis 1 ) modify degree impair glucose tolerance , underlie b-cell function cardiovascular risk factor profile , 2 ) improve patient-centered outcome quality life functionality , 3 ) modify specific sub-populations T-cells affect differentiation activation , 4 ) modify activation circulate immune cell , pro-inflammatory cytokine , hormone . Design : Double-blind , randomize , placebo-controlled trial , Phase II . Patient population : 34 patient active Psoriatic Arthritis meeting CASPAR ( ClASsification criterion Psoriatic ARthritis ) . Intervention : Participants randomize ( 1:1 ) liraglutide ( 1.2 mg sc daily ) placebo ( sc daily ) 12 week . Endpoints : The primary endpoint study proportion patient experience 20 % ACR ( American College Rheumatology ) improvement response follow liraglutide therapy compare placebo .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients active psoriatic arthritis ( 3 tender swollen joint ) meeting CASPAR study group criterion BMI &gt; 35 kg/m2 Uncontrolled diabetes , HbA1c &gt; 10.5 % Current biological treatment inflammatory disorder within past three month renal dysfunction ( eGFR &lt; 50 ml/min/1.73m macroalbuminuria &gt; 300mg ) hepatic dysfunction ( AST ( aspartate aminotransferase ) , ALT ( alanine aminotransferase ) , Total bilirubin &gt; 3 time upper limit normal ) history pancreatitis personal family history medullary thyroid cancer , ccell hyperplasia , MEN2 syndrome current pregnancy current breast feeding use DPP4 ( dipeptidyl peptidase4 inhibitor ) GLP1 receptor agonist within 2 month ( washout permit ) drug alcohol dependence rest tachycardia &gt; 100 bpm conduction abnormality associate tachycardia current enrollment clinical trial symptomatic gastroparesis concomitant serious medical condition medication treatment Psoriatic Arthritis MTX ( methotrexate ) &lt; 25 mg , LFN ( leflunomide ) &lt; 20 mg , NSAIDs ( nonsteroidal antiinflammatory drug ) use stable dos least 4 week , initiate least 3 month prior study start ( 8 week screen , 4 week baseline ) MTX LFN least 4 week NSAIDs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>liraglutide , GLP-1 receptor agonist</keyword>
</DOC>